版本:
中国

BRIEF-Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study

Nov 30 Helix Biopharma Corp -

* Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. Phase I study

* FDA accepted accelerated escalation scheme for l-dos47 dosing in U.S. Phase I study (ldos001) up to 12g/kg with pemetrexed/carboplatin Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐